Ready to go slide decks that Chapter Leaders can use for their Spring or Fall Learning Series. Once a chapter has presented a slide deck, they may not present it again. To obtain the actual slide deck, contact Mariel.


Recommending Exercise in those with Obesity and Cardiovascular Risk Factors (1 CE)

Learning Objectives

  • Review CV risk factors, their relationship, association and prevalence in persons with obesity.
  • Discuss ASCVD risk calculators and demonstrate how to calculate 10-year and lifetime ASCVD risk.
  • List the steps in performing a comprehensive  cardiovascular physical assessment to screen for safety in starting an exercise program.
  • Describe best practices in exercise counseling and prescription in persons with obesity.


Peripheral Arterial Disease: Risk Factors, Screening & Treatment (1 CE)

Learning Objectives

  • Outline the risk factors associated with PAD.
  • Describe the clinical presentation of patients with PAD.
  • List the steps to perform an Ankle Brachial Index (ABI) to screen for PAD.
  • Discuss common treatments for PAD including a supervised exercise training (SET) program for patients with claudication.

National Guidelines for the Primary Prevention of CVD: Integrating Hypertension, Cholesterol, Diabetes, and Lifestyle Guidelines into Practice (1.5 CE)

Learning Objectives

  • Cite and locate national guidelines related to CVD Risk Reduction
  • Using a case study approach, apply current CVD prevention and risk reduction guidelines to patient care planning.
  • Explain how CV risk assessment tools and patient-centered approaches can help to individualize risk factor management.
  • Describe how to identify and manage CV risk factors according to current guideline recommendations.

Diabetes and the CV Nurse: A Stepwise Approach to Management (1.0 CE, 0.6 Pharma)

Learning Objectives

  • Describe the association between diabetes and cardiovascular disease (CVD) and Chronic Kidney Disease (CKD).
  • Review ADA standards of care and CVD and CKD risk reduction.
  • Summarize clinical trial data supporting the use of antidiabetic therapy to improve CVD and CKD outcomes.
  • Explain a multidisciplinary, team-based approach to management of the patient with Type 2 Diabetes and the role of the CV clinician.


Anti-hyperglycemic therapies: Improving CVD outcomes and hemoglobin A1c (1 CE)

Learning Objectives

  • Describe the new challenge for cardiology in prescribing medications to manage diabetes as well as CVD
  • Review recent clinical trials of anti-hyperglycemic therapies, CV out comes
  • Discuss appropriate anti-hyperglycemic therapy selection, dose and potential side effects with new therapies
    Review Case Studies as examples

Hypertension Guideline: Emphasis on Risk (1 CE)

Learning Objectives

  • Review the new  definition of hypertension and the categories of blood pressure in adults according to the new (2017) hypertension guidelines.
  • Describe the association between high blood pressure and cardiovascular disease risk.
  • List treatment strategies for hypertension according to patients level and risk, co-morbidities, race/ethnicity and age.

Lipid Management: Incorporating Recent Data into Clinical Practice (1 CE)

Learning Objectives

  • Review current treatment guidelines for the management of dyslipidemia
  • Analyze recent clinical outcomes trials of PCSK9 inhibitor therapies in patients with ASCVD, Familial Hyperlipidemia and Diabetes
  • Discuss the relative value of PCSK9 inhibitor therapy considering costs and outcomes
  • Review best practice strategies to insure patients have access to needed CVD therapies

Screening for Non-Valvular Atrial Fibrillation: Identifying the Undiagnosed Patient (1 CE)

Learning Objectives

  • Review prevalence and common risk factors associated with non-valvular atrial fibrillation (NVAF).
  • Describe typical signs and symptoms of NVAF and how to assess for them during a clinical encounter.
  • Discuss the importance of pulse taking and follow up ECG to screen high risk patients for NVAF.
  • Using case examples, illustrate how to initiate NVAF treatment, provide follow-up and collaboration across the continuum of care to ensure optimal patient outcomes.

Women’s Cardiovascular Care Across the Life Course – Promoting Prevention During Pregnancy and the Postpartum and Childbearing Years (1 CE)

Learning Objectives

  • Identify three pregnancy complications associated with future cardiovascular or cardiometabolic risk
  • Identify women who are at increased risk for developing these pregnancy-related complications
  • Describe the cardiovascular or cardiometabolic risk associated with these pregnancy-related complications
  • Describe clinical guidelines and recommendations for postpartum follow up and risk reduction in women with histories of these pregnancy-related complications
  • Apply evidence-based interventions to promote healthy eating, physical activity, and breastfeeding during the postpartum and childbearing years


Antiplatelet Therapy Post Acute Coronary Syndrome: Choosing the Right Therapy for the Right Duration (1.0 CE, 0.7 Pharm)

Learning Objectives

  • List guideline-recommended antiplatelet therapies and indications for their use in the post-ACS patient.
  • Identify the most appropriate choice and duration of antiplatelet therapy in selected case studies.
  • Outline strategies to improve patient understanding and adherence to long-term antiplatelet therapies.

Heart Failure Guideline Update: Medications, Diagnosis and Co-Morbidities (1.0 CE, 0.5 Pharm)  

Learning Objectives

  • Understand the recommendations of pharmacotherapies from the 2016 heart failure guideline update
  • Identify the newest recommendations for initial and serial testing using biomarkers in patients with heart failure
  • Change practice based on new information for patients with heart failure with preserved ejection fraction (HFpEF)           
  • Recognize guideline supported strategies for managing comorbidities in patients with HF, including hypertension, anemia and sleep apnea

Making the Link: Cardiometabolic Risk, Diabetes and Cardiovascular Disease (1.0 CE)

Learning Objectives

  • Describe the relationship between cardiometabolic risk factors, diabetes and cardiovascular disease (CVD)
  • Outline a cardiometabolic risk reduction plan for patients at risk for diabetes and cardiovascular disease
  • Describe how accepted behavior change strategies can increase the rate of lifestyle and pharmacologic treatment adherence

Preventing and Managing VTE: Matching Patient Need to Optimal Therapy (1.0 CE, 0.5 Pharm)

Learning Objectives

  • Identify prevalence rates of venous thromboembolism (VTE), including rates for morbidity and mortality
  • Define professional guidelines for assessing risk in patients with VTE and discuss recommendations for patient management
  • Describe methods and tools for ensuring effective communication with patients and caregivers as a means of improving adherence and self-care in patients with VTE

Strategies for Managing Dyslipidemia Patients with Residual CVD Risk  (1.0 CE, 0.8 Pharm)      

Learning Objectives

  • Outline secondary prevention strategies in CVD patients with residual risk despite taking the maximum tolerated dose of statin therapy
  • Describe the clinical steps taken to identify statin intolerance (statin-associated adverse effects)
  • Differentiate between the indications for statins, PCSK9 inhibitors, and other LDL-lowering therapies


Diabetes and Cardiovascular Disease (CVD): Managing Patients with High Risk and Co-Morbid Conditions (1.0 CE, 0.5 Pharm)

Learning Objectives

  • Summarize the treatment recommendations for patients with diabetes to reduce their risk of cardiovascular disease
  • Describe the relationship between acute coronary syndrome (ACS) and hyperglycemia in patients with diabetes mellitus
  • Describe how using shared decision-making with a complex patient can increase the rate of treatment adherence

Strategies for Managing Dyslipidemia Patients with Residual CVD Risk (1.0 CE, 0.8 Pharm)        

Learning Objectives

  • Outline secondary prevention strategies in CVD patients with residual risk despite taking the maximum tolerated dose of statin therapy.
  • Describe the clinical steps taken to identify statin intolerance
  • Differentiate between the indications for statins, PCSK9 inhibitors and other LDL-lowering therapies
  • Identify the potential barriers to treatment adherence for patients requiring LDL-lowering therapies and solutions to address the barriers.


The Secondary Prevention Cocktail: The Key Ingredients (1.0 CE, 0.5 Pharm)

Learning Objectives

  • Review the secondary prevention guidelines for the post-ACS patient.
    Describe best practice recommendations for navigating the challenging hospital to home transition for the ACS patient
  • List the specific strategies that have proven efficacy for patients at risk for non-adherence.


Heart Healthy Lifestyle Counseling: A Focus on the Female Patient (1.0 CE)

Learning Objectives

  • Identify two pregnancy complications associated with future CVD risk
  • Describe the integration of brief dietary counseling into a clinical visit
  • Apply evidence-based interventions to promote physical activity and healthy eating including the PCNA Heart Healthy Toolbox.